Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…
Works with existing systems, helps lens makers stay ahead of global regulationsPITTSBURGH--(BUSINESS WIRE)--PPG (NYSE:PPG) today announced the launch of PPG…
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED)…